Compare · PALI vs XOMA
PALI vs XOMA
Side-by-side comparison of Palisade Bio Inc. (PALI) and XOMA Royalty Corporation (XOMA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. PALI focuses on Biotechnology: Biological Products (No Diagnostic Substances), while XOMA focuses on Biotechnology: Pharmaceutical Preparations.
- XOMA is the larger of the two at $503.8M, about 1.5x PALI ($342.0M).
- Over the past year, PALI is up 108.1% and XOMA is up 55.1% - PALI leads by 53.0 points.
- XOMA has been more active in the news (13 items in the past 4 weeks vs 8 for PALI).
- Both have 7 recent analyst ratings on file.
- Company
- Palisade Bio Inc.
- XOMA Royalty Corporation
- Price
- $1.96+4.81%
- $40.32-8.74%
- Market cap
- $342.0M
- $503.8M
- 1M return
- +9.50%
- -3.49%
- 1Y return
- +108.07%
- +55.08%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1986
- News (4w)
- 8
- 13
- Recent ratings
- 7
- 7
Palisade Bio Inc.
Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress, such as results from reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad, California.
XOMA Royalty Corporation
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and X213, an allosteric inhibitor of prolactin action;. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; Takeda Pharmaceutical Company Limited; and Cadila Healthcare Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Latest PALI
- Director Baltera Robert Jr. bought $88,698 worth of shares (45,000 units at $1.97), increasing direct ownership by 11% to 461,904 units (SEC Form 4)
- Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
- Director Baltera Robert Jr. bought $102,084 worth of shares (50,000 units at $2.04), increasing direct ownership by 14% to 416,904 units (SEC Form 4)
- Chief Medical Officer Jones Mitchell Lawrence converted options into 131,167 shares and sold $106,536 worth of shares (51,880 units at $2.05), increasing direct ownership by 539% to 94,009 units (SEC Form 4) to satisfy tax liability
- CEO, CFO Finley John David exercised 335,300 shares at a strike of $0.00 and sold $303,343 worth of shares (146,798 units at $2.07), increasing direct ownership by 646% to 217,688 units (SEC Form 4) to cover withholding tax
- SEC Form 144 filed by Palisade Bio Inc.
- Director Baltera Robert Jr. bought $59,400 worth of shares (30,000 units at $1.98), increasing direct ownership by 9% to 366,904 units (SEC Form 4)
- Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
- Director Baltera Robert Jr. was granted 336,904 shares (SEC Form 4)
- SEC Form 3 filed by new insider Baltera Robert Jr.
Latest XOMA
- SEC Form 4 filed by Large owner Bvf Partners L P/Il
- Chief Legal Officer Montano Maricel Perea disposed of 42,371 shares, closing all direct ownership in the company (SEC Form 4) to cover withholding tax
- Director Limber Joseph M disposed of 9,532 shares, returned 10,000 units of 8.625% Series A Cumulative Perpetual Preferred Stock to the company and returned 20,000 units of Depositary Shares - 8.375% Series B Cumulative Stock to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)
- Chief Investment Officer Sitko Bradley disposed of 86,702 shares, returned 395 units of 8.625% Series A Cumulative Perpetual Preferred Stock to the company and returned 9,045 units of Depositary Shares - 8.375% Series B Cumulative Stock to the company, closing all direct ownership in the company (SEC Form 4) to cover withholding tax
- Chief Executive Officer Hughes Owen disposed of 192,016 shares and returned 102,000 units of Depositary Shares - 8.375% Series B Cumulative Stock to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)
- Director Kosacz Barbara disposed of 6,269 shares, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Director Wyszomierski Jack L disposed of 21,828 shares, closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax
- Director Perry Matthew D disposed of 24,138 shares, closing all direct ownership in the company (SEC Form 4) (withholding obligation)
- Director Hernday Natasha disposed of 9,304 shares and returned 4,000 units of 8.625% Series A Cumulative Perpetual Preferred Stock to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Chief Financial Officer Trigilio Jeffrey disposed of 103,906 shares, closing all direct ownership in the company (SEC Form 4) (withholding obligation)